摘要
“态靶辨证”是仝小林院士提出的中医临床辨治新方略,其内涵是在现代诊断基础上强调疾病的“分类-分期-分证”及“宏观调态与微观打靶相结合”的辨治模式。肺癌态靶辨治体系的构建,以态靶辨证理论为指导,从肺癌发生发展的时序性演进轨迹和宏微观变化特征出发,将肺癌发病过程分为“郁、痰、瘀、损”四态,并态下分证,结合临床经验与现代药理学研究成果,确定相应的靶方靶药,态靶同调,为肺癌的中医临床诊疗提供新思路。
The"state-target treatment based on syndrome differentiation"is a new strategy for the clinical syndrome differentiation and treatment in traditional Chinese medicine proposed by Academician Tong Xiaolin,whose connotation lies in the combination of"classification-stage-syndrome"and the combination of"macroscopic state regulating and microscopic syndrome targeting"as a novel syndrome differentiation and treatment mode on the basis of modern diagnosis.Based on the therapeutic advantages of traditional Chinese medicine in intervening lung cancer,and guided by the theory of"state-target treatment based on syndrome differentiation",this article means to clarify the temporal evolution trajectory and macro-micro change characteristics of lung cancer in its occurrence and development,dividing the process of lung cancer into four states of"depression,phlegm,blood stasis,and weakness",and identifying specific syndromes under each state.Based on clinical experience and modern pharmacological research results in this respect,the study tries to determine corresponding target prescriptions and target drugs for those syndromes,and to construct a system for the lung cancer state-target treatment based on syndrome differentiation,in a bid to provide new ideas for traditional Chinese medicine clinical diagnosis and treatment of lung cancer.
作者
肖冲
吴昊
何莉莎
李雪珂
由凤鸣
XIAO Chong;WU Hao;HE Lisha;LI Xueke;YOU Fengming(Affiliated Hospital of Chengdu University of Traditional Chinese Medicine,Chengdu 610075,China;Department of Oncology,Chengdu University of Traditional Chinese Medicine,Chengdu 610000,China)
出处
《吉林中医药》
2024年第10期1134-1137,共4页
Jilin Journal of Chinese Medicine
基金
国家自然科学基金青年基金项目(82205072)
中国博士后科学基金面上项目(2023MD734101)
四川省自然科学基金青年项目(2023NSFSC1815)。
关键词
态靶辨治
肺癌
分期识态
靶方靶药
state-target treatment based on syndrome differentiation
lung cancer
stage and state recognition
target prescription and target drug
